Table 1.
Clinicopathologic and demographic features of the studied bladder cancer patients
| variable | LDH | P value | FASN | P-value | |||
|---|---|---|---|---|---|---|---|
|
Normal
(≤ 245 U/L) |
High
(> 245 U/L) |
Normal
(≤15 pg/ml) |
High
(>15 pg/ml) |
||||
| Age | ≤50 (N=10) |
2 (20.0%) | 8 (80.0%) | 0.48 | 3 (30.0%) | 7 (70.0%) | 0.83 |
| >50 (N=90) |
33 (36.6%) | 57 (63.4%) | 35 (38.8%) | 55 (61.2%) | |||
| Gender | Male (N=73) |
25 (34%) | 48 (66%) | 0.29 | 38 (52.1%) | 35 (47.9%) | 0.07 |
| Female (N=27) |
13 (48.1%) | 14 (51.9%) | 8 (29.6%) | 19(70.4%) | |||
| Smoking | Yes (N=33) |
13 (39.3%) | 20 (60.7%) | 1.0 | 10 (30.3%) | 23 (69.7%) | 0.015 |
| No (N=67) |
25 (37.3%) | 42 (62.7%) | 39 (58.2%) | 28 (41.8%) | |||
| Tumor size | ≤ 3cm (N=70) |
33 (47.2%) | 37 (52.8%) | 0.89 | 42 (60.0%) | 28 (40.0%) | 0.48 |
| > 3cm (N=30) |
13 (43.3%) | 17 (56.7%) | 15 (50.0%) | 15 (50.0%) | |||
| Tumor Grade | PUNLMP* (N=18) |
8 (44.4%) | 10 (55.5%) | 0.61 | 11(61.2%) | 7 (38.8%) | 0.36 |
| Low grade (N=18) |
7 (38.8%) | 11 (61.2%) | 8 (45.4%) | 10 (54.6%) | |||
| High grade (N=64) |
24 (37.5%) | 40 (62.5%) | 30 (47.0%) | 34 (53.0%) | |||
| Tumor Stage | I-II (N=23) |
16 (69.5%) | 7 (30.5%) | 0.007 | 18 (78.5%) | 5 (21.5%) | 0.006 |
| III-IV (N=77) |
27 (35.0%) | 50 (65.0%) | 33(42.8%) | 44 (57.1%) | |||
|
Lympho-vascular
invasion |
No (N=55) |
40 (72.7%) | 15 (27.3%) | < 0.001 | 33 (60.0%) | 22 (40.0%) | 0.07 |
| Yes (N=45) |
15 (33.3%) | 30 (66.6%) | 18 (40.0%) | 27 (60.0%) | |||
* Fatty acid synthase (FASN), Lactate dehydrogenase (LDH), Papillary urothelial neoplasms of low malignant potential (PUNLMP)